Post-transplant cyclophosphamide for GVHD prophylaxis in pediatrics with chronic active Epstein-Barr virus infection after haplo-HSCT

Dunmire SK, Verghese PS, Balfour HH. Jr. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84–92. https://doi.org/10.1016/j.jcv.2018.03.001.

Article  PubMed  Google Scholar 

Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD. The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol. 2015;33:787–821. https://doi.org/10.1146/annurev-immunol-032414-112326.

Article  CAS  PubMed  Google Scholar 

Kimura H, Cohen JI. Chronic active Epstein-Barr virus disease. Front Immunol. 2017;8:1867. https://doi.org/10.3389/fimmu.2017.01867.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sawada A, Inoue M. Hematopoietic stem cell transplantation for the treatment of Epstein-Barr Virus-Associated T- or NK-Cell Lymphoproliferative Diseases and Associated Disorders. Front Pediatr. 2018;6:334. https://doi.org/10.3389/fped.2018.00334.

Article  PubMed  PubMed Central  Google Scholar 

Okano M. Overview and problematic standpoints of severe chronic active Epstein-Barr virus infection syndrome. Crit Rev Oncol Hematol. 2002;44(3):273–82. https://doi.org/10.1016/s1040-8428(02)00118-x.

Article  PubMed  Google Scholar 

Kimura H, Morishima T, Kanegane H, Ohga S, Hoshino Y, Maeda A, et al. Prognostic factors for chronic active Epstein-Barr virus infection. J Infect Dis. 2003;187(4):527–33. https://doi.org/10.1086/367988.

Article  PubMed  Google Scholar 

Cohen JI, Jaffe ES, Dale JK, Pittaluga S, Heslop HE, Rooney CM, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–49. https://doi.org/10.1182/blood-2010-11-316745.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebihara Y, Manabe A, Tanaka R, Yoshimasu T, Ishikawa K, Iseki T, et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;31(12):1169–71. https://doi.org/10.1038/sj.bmt.1704078.

Article  CAS  PubMed  Google Scholar 

Taketani T, Kikuchi A, Inatomi J, Hanada R, Kawaguchi H, Ida K, et al. Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2002;29(6):531–3. https://doi.org/10.1038/sj.bmt.1703392.

Article  CAS  PubMed  Google Scholar 

Fujii N, Takenaka K, Hiraki A, Maeda Y, Ikeda K, Shinagawa K, et al. Allogeneic peripheral blood stem cell transplantation for the treatment of chronic active Epstein-Barr virus infection. Bone Marrow Transplant. 2000;26(7):805–8. https://doi.org/10.1038/sj.bmt.1702600.

Article  CAS  PubMed  Google Scholar 

Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for Leukemia. Clin Cancer Res. 2015;21(9):2020–8. https://doi.org/10.1158/1078-0432.CCR-14-0586.

Article  PubMed  Google Scholar 

Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD Consortium. Blood. 2011;117(17):4651–7. https://doi.org/10.1182/blood-2010-11-319509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24(11):1852–8. https://doi.org/10.1038/leu.2010.187.

Article  CAS  PubMed  Google Scholar 

Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for blood and marrow transplantation. Lancet Haematol. 2020;7(2):e157-e67. https://doi.org/10.1016/S2352-3026(19)30256-X.

Article  Google Scholar 

Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant. 2014;49(2):168–73. https://doi.org/10.1038/bmt.2013.107.

Article  CAS  PubMed  Google Scholar 

Dou L, Hou C, Ma C, Li F, Gao X, Huang W, et al. Reduced risk of chronic GVHD by low-dose rATG in adult matched sibling donor peripheral blood stem cell transplantation for hematologic malignancies. Ann Hematol. 2020;99(1):167–79. https://doi.org/10.1007/s00277-019-03884-8.

Article  PubMed  Google Scholar 

Zuckerman T, Rowe JM. Alternative donor transplantation in acute myeloid leukemia: which source and when? Curr Opin Hematol. 2007;14(2):152–61. https://doi.org/10.1097/MOH.0b013e328017f64d.

Article  PubMed  Google Scholar 

Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–50. https://doi.org/10.1016/j.bbmt.2008.03.005.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep. 2011;3(Suppl 2):e15. https://doi.org/10.4081/pr.2011.s2.e15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kasamon YL, Luznik L, Leffell MS, Kowalski J, Tsai HL, Bolanos-Meade J, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010;16(4):482–9. https://doi.org/10.1016/j.bbmt.2009.11.011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010;115(16):3224–30. https://doi.org/10.1182/blood-2009-11-251595.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bailen R, Kwon M, Pascual-Cascon MJ, Ferra C, Sanz J, Gallardo-Morillo A, et al. Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation. Ann Hematol. 2021;100(2):541–53. https://doi.org/10.1007/s00277-020-04317-7.

Article  CAS  PubMed  Google Scholar 

Yonese I, Sakashita C, Imadome KI, Kobayashi T, Yamamoto M, Sawada A, et al. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification. Blood Adv. 2020;4(13):2918–26. https://doi.org/10.1182/bloodadvances.2020001451.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, et al. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022;97(6):780–90. https://doi.org/10.1002/ajh.26544.

Article  CAS  PubMed  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-8.

Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389–401 e1. https://doi.org/10.1016/j.bbmt.2014.12.001.

Article  PubMed  Google Scholar 

Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339–48. https://doi.org/10.1056/NEJMsa1311707.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10–24. https://doi.org/10.1038/nrclinonc.2015.128.

Article  CAS  PubMed  Google Scholar 

Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997;15(5):1767–77. https://doi.org/10.1200/JCO.1997.15.5.1767.

Article  CAS  PubMed  Google Scholar 

Apperley J, Niederwieser D, Huang XJ, Nagler A, Fuchs E, Szer J, et al. Haploidentical hematopoietic stem cell transplantation: A global overview comparing Asia, the European Union, and the United States. Biol Blood Marrow Transplant. 2016;22(1):23–6. https://doi.org/10.1016/j.bbmt.2015.11.001.

Article  PubMed  Google Scholar 

Maegaki M, Kawamura K, Hara K, Hosoda R, Suzuki S, Hosoda Y, et al. Successful HLA-haploidentical stem cell transplantation with post-transplant cyclophosphamide in an older patient with chronic active Epstein-Barr virus infection. Int J Hematol. 2022;116(4):630–4. https://doi.org/10.1007/s12185-022-03345-5.

Article  CAS  PubMed  Google Scholar 

Battipaglia G, Labopin M, Kroger N, Vitek A, Afanasyev B, Hilgendorf I, et al. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood. 2019;134(11):892–9. https://doi.org/10.1182/blood.2019000487.

Article  CAS  PubMed  Google Scholar 

Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein-Barr virus infection. Int J Hematol. 2017;105(4):406–18. :https://doi.org/10.1007/s12185-017-2192-6.

Article  CAS  PubMed  Google Scholar 

Song Y, Yin Z, Ding J, Wu T. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation is a good choice for Acute myeloid leukemia and myelodysplastic syndrome: a Meta-analysis of Randomized controlled trials. Front Oncol. 2021;11:708727. https://doi.org/10.3389/fonc.2021.708727.

留言 (0)

沒有登入
gif